Pharmacoeconomic Guidelines: Taiwan

Country/Region: Taiwan
PE Guidelines
PE Guidelines Source:
Taiwan Society for Pharmacoeconomics and Outcomes Research

Information current as of Tuesday, January 23, 2018

Key Features

Type of Guidelines PE Guidelines
Title and year of the document Guidelines of Methodological Standards for Pharmacoeconomic Evaluations (2006)
Affiliation of authors Taiwan Society for Pharmacoeconomic and Outcomes Research (TaSPOR)
Purpose of the document Provide stakeholders a guide to conduct, evaluate and report a PE study
Standard reporting format included Yes
Disclosure Yes
Target audience of funding/ author's interests Should state clearly
Perspective Mainly societal, may separate into payer and others
Indication Should be approved by the regulatory body
Target population State clearly, may include subgroup analysis
Subgroup analysis Yes. Treatment regimen, disease groups, symptom complex, severity of disease, patient characteristics
Choice of comparator The one most likely to be replaced, first choice, most effective one, most frequently used.
Time horizon Long enough to cover all significant clinical and cost consequences that are directly related to the intervention.
Assumptions required Yes
Preferred analytical technique The most appropriate method that can reflect the purpose of the study
Costs to be included Depends on the perspective of the study. Recommend human capital approach for estimation of indirect cost
Source of costs Direct costs from BNHI reimbursement price, state clearly the sources, reflect Taiwan situations
Modeling Yes, requires details
Systematic review of evidences Recommended
Preference for effectiveness over efficacy Yes. Recommend meta-analysis of effectiveness.
Preferred outcome measure Life-year gained and QALY
Preferred method to derive utility All can be accepted, using general public’s views
Equity issues stated Yes
Discounting costs Base: 3%; SA: 0 ~ 5%
Discounting outcomes Three scenarios: discount cost but not outcome, both discounted, both not discounted
Sensitivity analysis-parameters and range All assumptions should be subject to SA.
Sensitivity analysis-methods Univariate, Multivariate (best and worst case estimate),
Presenting results Both in aggregated and disaggregated form
Incremental analysis Yes
Total costs vs effectiveness (cost/effectiveness ratio) Yes
Portability of results (Generalizability) Yes, Taiwan context, especially the cost issue and epidemiology data
Financial impact analysis Yes
Mandatory or recommended or voluntary Voluntary


Tony Yen-Huei Tarn contributed to the key feature form.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now